エンライベックス
Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 27.35 | $0 | -$3M |
| 2025 Q3 | -0.09 | $0 | -$2M |
| 2025 Q2 | -0.08 | $0 | -$1M |
| 2025 Q1 | -0.16 | $0 | -$5M |
| 2024 Q4 | -0.24 | $0 | -$4M |
| 2024 Q3 | -0.12 | $0 | -$3M |
| 2024 Q2 |
| -0.16 |
| $0 |
| -$2M |
| 2024 Q1 | -0.22 | $0 | -$5M |